A 28 year old woman, recently diagnosed as having a first deep venous thrombosis (DVT), visits her general practitioner. She has no predisposing factors (such as surgery, trauma, or malignancy), and tests show no familial thrombophilia risk factors, such as factor V Leiden. She had been using a combined oral contraceptive containing ethinylestradiol 30 µg and levonorgestrel 150 µg but was advised at the hospital to stop this as it increased her risk of getting another DVT. She now asks about contraceptive options that do not put her at risk for another DVT, particularly hormonal options, as she has been told they are more effective than non-hormonal contraceptives.
Venous thromboembolism (VTE) is a common disease with an overall annual incidence of 1 in 1000 people and an estimated mortality rate of 370 000 deaths per year in six European countries. 1 2 The overall incidence of a recurrent thrombotic event is 20-30% in 10 years, with the highest rate in the months after discontinuation of anticoagulation therapy. 3 As the risk of VTE is increased in women using combined oral contraceptives (that is, containing both oestrogen and progestogen) and hormone replacement therapy, this article aims to provide advice for women with a history of VTE who require contraception or hormone replacement therapy.
Which contraceptive has the lowest VTE recurrence risk? Table 1⇓ shows the results from our literature search. The risk of a recurrent event was approximately 1% per year in a prospective cohort study of women who discontinued oral contraceptive use after their first event. 4 As the study was conducted in relatively young, female patients, risk of recurrence was lower than in the general population. A retrospective cohort study that included a large number of participants with hereditary thrombophilias (for example, factor V Leiden (19.2%) and protein S deficiency (13%)) found a slightly higher risk of 3% per year.
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Combined oral contraceptives
A prospective cohort study showed that major classes of combined oral contraceptives were associated with higher risk of recurrence of VTE, especially triphasic contraception containing levonorgestrel (absolute risk 13.9% per year). 4 Thus, women with a history of VTE should avoid combined oral contraceptives.
Progestogen only contraceptives
A retrospective cohort study reported that oral progestogen only therapy did not significantly increase the risk of VTE recurrence (absolute risk 3.3% per year in oral progestogen users versus 2.5% per year in non-users). 5 In a prospective cohort study, recurrences in patients treated with progestogen only therapy occurred exclusively in those using injectable preparations. 4 As neither cohort study adjusted for multiple factors associated with VTE recurrence that presumably influence decisions about treatment (such as overweight and familial thrombophilia factors), this may have introduced confounding by indication. In addition, small sample sizes lower the quality of these studies. Thus, the evidence is limited but suggests that women with a history of VTE can take the progestogen only pill but should avoid injectable progestogens. No evidence exists on the effect of the levonorgestrel releasing intrauterine device or progestogen only implant on risk of recurrent VTE.
Which contraceptive has the lowest primary VTE risk?
As evidence on recurrent VTE risk is scarce, we also reviewed evidence on hormonal contraceptives predisposing to a first episode of VTE ( 
Methods
We did a systematic search in PubMed, Embase, and the Cochrane Library, updated to July 2014. Search terms were synonyms of contraceptives/hormonal therapy, venous thromboembolism, and recurrence. Our search yielded 685 articles, which we screened on title, abstract, or both. Seven were suitable for full text screening. We excluded two articles because the primary outcome was elevation of inflammatory markers (such as C reactive protein) instead of recurrence of VTE and one because the researchers did not explicitly study various types of contraceptives. Finally, we critically appraised two relevant articles on contraception and two on hormone therapy for postmenopausal women. We used the PRISMA statement to assess studies on risk of recurrence of VTE for directness of evidence and risk of bias. Studies had small study populations and a reasonably high risk of bias because of missing data (6-24%) and inadequate adjustment for confounders.
those for recurrent VTE. 3 6 The risk of a first VTE in women not using any hormonal contraceptive is 0.02% per year. 
Combined oral contraceptives
If women use a pill with a second generation progestogen such as levonorgestrel, their risk of primary VTE is approximately 0.06% per year, lower than the risk if they use a pill with a third generation or fourth progestogen such as gestodene, desogestrel, or drospirenone (0.07-0.10% per year). [7] [8] [9] [10] [11] [12] The pill containing 30-40 µg ethinylestradiol with norethisterone seemed to have the lowest risk of first thrombosis (0.029% per year). 7 Furthermore, VTE risk seems to rise with the dose of ethinylestradiol. 8 Thus, although combined oral contraceptives raise the risk of VTE, the absolute risk for a first event is still low.
Progestogen only contraceptives
Users of oral progestogens or the levonorgestrel intrauterine device do not seem to have a higher risk for primary VTE than do women not using contraception. 7 13-15 Although based on less strong evidence, the subcutaneous implant that releases etonogestrel also seems not to be associated with primary VTE. 14 The World Health Organization's 2015 "Medical Eligibility Criteria" guideline states that the benefits of injectable progestogen only contraception (medroxyprogesterone) generally outweigh the risks in women with and without a history of VTE. 16 17 However, a 2010 case-control study showed that these preparations do raise the risk of first VTE substantially. 15 This higher VTE risk in users of injectable progestogens was confirmed by a meta-analysis combining all available evidence, 13 although this is very limited as it was based on two small case-control studies.
Thus, oral progestogens, the levonorgestrel intrauterine device, and the subcutaneous implant are not associated with primary VTE, whereas injectable progestogen may raise risk of primary VTE.
Other types of combined contraceptives
Both a prospective cohort study and a nested case-control study found that patch users (ethinylestradiol/norelgestromin) had an increased risk (absolute risk 0.097% and 0.053% per year). 14 18 The vaginal ring contains a combination of ethinylestradiol and etonogestrel and raises risk of VTE (absolute risk 0.078% per year).
14 Thus, both transdermal contraceptives and the vaginal ring may increase risk of primary VTE.
What is the contraceptive effectiveness of hormonal and non-hormonal preparations?
The risk of VTE associated with a preparation; its contraceptive effectiveness, side effects, and contraindications; and patients' preferences should be weighed when making a decision about treatment. 16 Table 3⇓ outlines the contraceptive effectiveness and key disadvantages of different contraceptive techniques. In summary:
• Hormonal preparations-These are effective contraceptives but have different side effect profiles. The only comparative trial of progestogen only pills showed that the effectiveness of oral desogestrel 75 µg and levonorgestrel 30 µg is high (99.9% and 98.8%, respectively). 19 20 Progestogen only pills may be less effective than combined oral contraceptives in daily practice, as the traditional progestogen only pills cannot be taken more than three hours late, and desogestrel not more than 12 hours late, for reliability. Irregular bleeding is a common side effect of the progestogen only pill.
• Barrier methods-These do not increase the risk of VTE but are less effective contraceptives than hormonal methods.
• Copper intrauterine device and sterilisation-These are effective contraceptives and do not increase VTE risk, but the copper intrauterine device might cause menorrhagia or dysmenorrhoea, and sterilisation is a permanent method.
How should a woman with a history of VTE who requires contraception be treated?
Avoid combined oral contraceptives, as they may increase the risk of recurrent VTE. 4 5 First choice contraceptives are effective non-hormonal preparations, such as the copper intrauterine device. If non-hormonal contraceptive options are discussed and found unsuitable, we would recommend a levonorgestrel intrauterine device in women who wish to continue contraceptive use after a first VTE, as in our case scenario. This is based on 14 15 as no data are available on the risk of recurrent deep venous thrombosis. Another option would be the progestogen only pill, as studies show no increased risk of recurrent or primary VTE in its users. 5 7 13 However, contraceptive effectiveness and adherence to therapy may be lower with oral progestogens than with a levonorgestrel intrauterine device. A subcutaneous implant would be a third option, although based on less strong evidence and extrapolated from primary VTE data.
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How should a woman with a history of VTE and menorrhagia be treated?
Progestogens are often prescribed for women with menorrhagia. Observational studies found that the progestogen only pill or levonorgestrel intrauterine device did not increase the risk of primary or secondary VTE. 4 5 7 13 14 However, high dose oral progestogens (norethisterone 10-20 mg) might be associated with increased VTE recurrence risk and should be used with caution. If menorrhagia requires treatment with high dose oral progestogens, a small comparative study suggests that medroxyprogesterone 10 mg three times daily is as effective in reducing severe menstrual bleeding as high dose norethisterone. 21 Thus, medroxyprogesterone might be a safer treatment option for women with menorrhagia and a history of VTE.
How should a woman with a history of VTE and menopausal symptoms be treated?
For a postmenopausal woman with severe vasomotor symptoms (hot flushes, night sweats), systemic oestrogen treatment is most effective. The only randomised controlled trial on risk of VTE recurrence in postmenopausal women was ended prematurely as preliminary results showed that patients taking combined oral oestradiol (2 mg) and norethisterone acetate (1 mg) had a higher risk of recurrence (absolute risk 8.5% (95% confidence interval 2.6% to 14.4%) per year) than did those taking placebo (1.1% (0% to 3.2%) per year). 22 A cohort study (n=1023; 77 recurrent VTEs) found transdermal oestrogen therapy with or without progestogen not to be associated with recurrent VTE in postmenopausal women (absolute risk 1.3% per year in patients with transdermal oestrogens versus 1.1% per year in non-users; hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). 23 This result did not change when corrected for age, overweight, obesity, and whether the first event was idiopathic or secondary. However, oral oestrogen increased VTE recurrence risk in patients in this study, although the numbers were too small for definitive conclusions to be drawn. 23 A case-control study found transdermal oestrogen therapy not to be associated with primary VTE risk either. 24 Thus, in the absence of more rigorous evidence, we advise use of transdermal oestrogen therapy in patients with severe menopausal symptoms. In women with an intact uterus, add progestogens for endometrial protection. 25 Oral dydrogesterone (10 mg for 14 days a month), oral medroxyprogesterone (5-10 mg for 14 days a month), or micronised progesterone (200 mg for 12-14 days a month) do not seem to increase VTE recurrence risk.
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How should a woman with a history of VTE and conditions associated with deficiency of female sex hormones be treated?
Rare disorders associated with a deficiency of female sex hormone secretion include idiopathic hypogonodatropic hypogonadism, a hypophyseal adenoma, Kallman's syndrome, Sheehan's syndrome, and Turner's syndrome. For these women, we recommend transdermal oestrogen therapy in combination with oral progestogen or a levonorgestrel intrauterine device, on the basis of observational studies on secondary and primary VTE risk. 5 7 13 23 In those for whom hormonal deficiency resolves or is not severe, as female sex hormone secretion is sometimes reported in these disorders, appropriate contraception may be needed.
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